$FPH

Market quiet but earnings showing positive signs

Fisher & Paykel Healthcare upgraded its 2027 guidance, citing strong hospital product sales. Revenue and net profit forecasts increased, with first-half revenue expected at $1.24B and net profit at $280M. The stock closed at $43.52. On Wall Street, the Dow fell 1.32% as bond yields rose and Walmart missed earnings. In NZ, several companies reported earnings, including South Port NZ and Seeka.

Original reporting
Published Aug 21, 2026, 7:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 7:15 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Market quiet but earnings showing positive signs — source image
Decision brief

The 30-second read

$FPHBullishMed
01

Why it matters

Guidance lift is the primary new information; other price moves are routine market reactions.

02

Market read

Guidance upgrade may drive short‑term buying interest in FPH and lift sentiment for NZ health‑care stocks.

03

What to watch

Potential supply‑chain constraints in hospital product group could temper growth.

Relevance 8/10Novelty 8/10Timing: today

Background

The article summarizes recent earnings and guidance updates across NZ‑listed companies, highlighting Fisher & Paykel Healthcare's upgraded outlook.

Company-level read

Ticker impact

$FPHBullishHigh confidence
Context

Fisher & Paykel Healthcare raised full-year revenue to $2.47‑$2.57 bn and net profit to $525‑$565 m, prompting a volatile session and a 57c price gain.

Expected impact

Potential upside of 3‑5% if market digests the guidance.

Evidence & confidence

Guidance beats consensus and includes concrete tariff refund benefit.

Market effects

Positive signal for NZ health‑care equipment sector.

Supports broader NZ market rally, especially domestic exporters.

Limited to investors tracking NZ equities and health‑care exposure.

Counterpoint

If tariff refunds are delayed, the upside may be overstated.

Key entities

  • Fisher & Paykel Healthcare

    NZ health‑care equipment maker that raised FY guidance.

Related articles

$FPHMed

FPH turns down KKR bid for First Gen stake over valuation

First Philippine Holdings (FPH) rejected KKR’s non-binding bid to buy an additional 8.43% stake in First Gen and then tender for First Gen’s public float at P36/share, saying it undervalues First Gen. FPH owns 67.84% of First Gen; KKR has 19.9% economic interest. The deal would have supported a delisting. First Gen also weighs a $5B offer from BREN for EDC.

$FPHMedAI 8/10

First Holdings thumbs down KKR offer

First Philippine Holdings (FPH) rejected KKR’s non-binding proposal to buy part of FPH’s stake in First Gen Corp. and to launch a voluntary tender offer for First Gen’s public float at PHP 35 per share. FPH said the offer does not reflect First Gen’s true value. KKR holds about 19.9% economic interest and plans delisting via the tender offer.

$FPHMed

First Phil Holdings rejects KKR bid for First Gen stake

First Philippine Holdings (FPH) said it rejected KKR’s non-binding bid to buy FPH’s 8.43% stake in First Gen and launch a voluntary tender offer for First Gen’s 11.67% public float at P35 per share. FPH said the proposal does not reflect First Gen’s true value and ended its participation. FPH shares fell P1 to P102; First Gen fell P3.50 to P27.20.

$KKRMed

Making sense of US firm KKR’s offer on Lopez family’s First Gen

KKR emailed First Philippine Holdings (FPH) and First Gen Corp. on July 10 with a three-step plan, disclosed in an Aug. 13 letter to the PSE. KKR would buy 8.43% of First Gen from FPH, then buy the 11.67% public float, and seek delisting. KKR says any change-of-control deal would trigger a mandatory tender offer and a control premium at least 30% above its offer price (about P46 vs ~P35).

$FPHMed

Lopez family confirms a sale inside ultimate parent firm Lopez Inc.

First Philippine Holdings (FPH) said director Roberta Lopez-Feliciano resigned effective Aug. 9, citing that Crème Investment Corporation sold its shares in Lopez Inc., the private parent above FPH. The filing was made under SEC Form 17-C Item 4 (director/officer change), not change in control. Crème held 25.68% of Lopez Inc.